NHVMAS congratulates the team at the Microbicide Trial Network for concluding and sharing with the rest of the world and we African women a most vital piece of information that helps us to learn more about the needs of African women. We consider the outcome of the study a most useful piece of information that makes it quite clear what we women in Africa needs.

The Vaginal and Oral Interventions to Control the Epidemic study, also known as the VOICE study, released yesterday by the National Institute of Allergy and Infectious Diseases, National Institutes of Health at CROI indicates that participants provided daily oral pre-exposure prophylaxis (PrEP) did not experience any protection against HIV compared to those in the placebo arm. This is likely because very few were taking the study drugs as directed as less than one-third of participants assigned to use the product had any study drug detected in their blood. The earlier arm of the study that was looking at tenefovir gel efficacy also showed that it was not protective against HIV infection probably for the same reason. The products are however safe for use in we African women.

While the study may be interpreted as a failure to demonstrate that daily oral Truvada and oral tenofovir pill and failure of daily tenofovir gel application in the vagina to prevent HIV infection in the study participants, we at NHVMAS however do view the study as part of the piece of a jigsaw that tells us a comprehensive story about ARV based prevention.

For we at NHVMAS and the voice we represent here in Nigeria, the iPrEx study, the Partners PrEP study, the TDF2 study, the Fem-PREP and now the VOICE study are all complementary: The  iPrEx study shows clearing that  PrEP using Truvada works in men who have sex with men (MSM) and transgender women who have sex with men; the Partners PrEP study showed clearly that PrEP using Truvada and tenofovir works with serodiscordant couples including the African women who participated in the study; the TDF2 study, conducted in heterosexual men and women in Botswana, also showed PrEP using tenofovir works. Effectiveness of these products however, depends on adherence.

The VOICE study confirms what the FEM-PREP study had earlier found – for we African women, adherence to once daily pill use is a challenge and thus for us, PrEP using a once daily pill regimen will not be effective. It confirms the literally existing evidence on ground that popping a daily pill for any reason when there is no hard need for it is a challenge for many of we African women.

We African women who bear the greatest burden of the disease therefore need our partners and friends to continue with their efforts at discovering products that will enable us take the needed precaution for HIV prevention. The overall HIV incidence of 4.7% in women engaged in the VOICE study is completely unacceptable.

We in Nigeria join voices with other African women to ask for global support for the FACTS 001 study which has the potential to show that tenofovir gel used on a coitally dependent basis may make a difference to our needs.

We need all our researcher friends and partners, our donors and all critical stakeholders to invest and continue to invest in the various ring studies that has the potential for long releases of active substances that can prevent against HIV.

We also need human and financial investments in new studies that have a potential for the development of long acting PrEP wherein we women may take a single effective does of PrEP that may last for many months. Something that closely simulates what we look for in contraceptives.

We ask for continued research into the development of a rectal microbicide as the VOICE study clearly adds more evidence to the knowledge: women in Africa do engage in anal sex.

The VOICE and the FEM-PREP study is the hard evidence of the African women voices. The VOICE and FEM-PREP studies are a few of the sciences we need as we go into the future that clearly tells the world about what we women in Africa – Nigeria inclusive – need when it comes to prevention products. We need products that take cognisance of the nuances of our daily lives. We live daily with stressful challenges that may make HIV prevention not top the list of our daily priorities. It does not mean we do not care about preventing ourselves from contracting HIV infection. It simply means we need products that can fit into the reality of our daily lives.

We join the rest of the world to thank all the 5,029 sisters from South Africa, Zimbabwe, and Uganda who volunteered to participate in the VOICE trial. We also commend the Microbicide Trials Network and the National Institutes of Health for successfully implementing an incredibly important trial that has contributed more to the science of HIV prevention.

We look forward to learning more about the potential contributions of culture, norms and the entire social enterprise that the study participants live in to what the VOICE study revealed. The MTN 003c and MTN 003d are important studies for us.